Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, Gatopoulou A, Karatzas P, Kopylov U, Michalopoulos G, Michopoulos S, Navaneethan U, Rubin DT, Siffledeen J, Singh A, Soufleris K, Stein D, Demuth D, Mantzaris GJ. Bressler B, et al. Among authors: bellaguarda e. J Crohns Colitis. 2021 Oct 7;15(10):1694-1706. doi: 10.1093/ecco-jcc/jjab058. J Crohns Colitis. 2021. PMID: 33786600 Free PMC article.
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.
Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT. Christensen B, et al. Among authors: bellaguarda e. Aliment Pharmacol Ther. 2018 Mar;47(6):753-762. doi: 10.1111/apt.14525. Epub 2018 Jan 29. Aliment Pharmacol Ther. 2018. PMID: 29377235 Free PMC article.
Checkpoint Inhibitor-Induced Colitis.
Bellaguarda E, Hanauer S. Bellaguarda E, et al. Am J Gastroenterol. 2020 Feb;115(2):202-210. doi: 10.14309/ajg.0000000000000497. Am J Gastroenterol. 2020. PMID: 31922959 Review.
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
Weaver KN, Zhang X, Dai X, Watkins R, Adler J, Dubinsky MC, Kastl A, Bousvaros A, Strople JA, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda E, Farraye FA, Boccieri ME, Firestine A, Kappelman MD, Long MD. Weaver KN, et al. Among authors: bellaguarda e. Inflamm Bowel Dis. 2022 Oct 3;28(10):1497-1505. doi: 10.1093/ibd/izab302. Inflamm Bowel Dis. 2022. PMID: 34871388 Free PMC article.
Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases.
Kappelman MD, Weaver KN, Zhang X, Dai X, Watkins R, Adler J, Dubinsky MC, Kastl A, Bousvaros A, Strople JA, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda EA, Farraye FA, Boccieri ME, Firestine A, Chun KY, Fernando M, Bastidas M, Zikry M, Long MD. Kappelman MD, et al. Among authors: bellaguarda ea. Am J Gastroenterol. 2022 Mar 1;117(3):462-469. doi: 10.14309/ajg.0000000000001619. Am J Gastroenterol. 2022. PMID: 35029167
28 results